Study of Bleeding With Extended Administration of an Oral Contraceptive
Launched by WARNER CHILCOTT · Jun 16, 2006
Trial Information
Current as of July 23, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy women
- • Age 25-40
- • History of regular cycles
- Exclusion Criteria:
- • Current or recent (within 2 months) users of hormonal contraceptives
- • Contraindications for use of hormonal contraception
- • Conditions which affect the absorption or metabolism of steroid hormones
- • BMI \> 35
About Warner Chilcott
Warner Chilcott is a leading pharmaceutical company specializing in the development and commercialization of innovative prescription products in the fields of women's health, urology, and dermatology. With a commitment to enhancing patient outcomes, Warner Chilcott focuses on delivering high-quality medications that meet the evolving needs of healthcare providers and patients. The company is dedicated to rigorous clinical research and adherence to regulatory standards, ensuring the safety and efficacy of its therapies. Through strategic partnerships and a robust pipeline, Warner Chilcott continues to advance healthcare solutions that improve the quality of life for individuals worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Phoenix, Arizona, United States
Tempe, Arizona, United States
Carmichael, California, United States
Boynton Beach, Florida, United States
Leesburg, Florida, United States
Miami, Florida, United States
West Palm Beach, Florida, United States
Decatur, Georgia, United States
Roswell, Georgia, United States
Peoria, Illinois, United States
Lexington, Kentucky, United States
Louisville, Kentucky, United States
New Bern, North Carolina, United States
Winston Salem, North Carolina, United States
Philadelphia, Pennsylvania, United States
Greenville, South Carolina, United States
Pleasant Grove, Utah, United States
Salt Lake City, Utah, United States
Sandy, Utah, United States
Virginia Beach, Virginia, United States
Seattle, Washington, United States
Patients applied
Trial Officials
Herman Ellman, MD
Study Director
Sponsor GmbH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials